Rare diseases
Investigational molecules
Locations
Recruiting trials first
28 clinical trials in this condition
Austria
Denmark
BelgiumBelgiumIn short
This article provides detailed information about 22 ongoing clinical trials for adenocarcinoma gastric (also known as gastric adenocarcinoma, stomach cancer). These trials are testing various treatment approaches including immunotherapy, targeted therapies, and combination chemotherapy regimens across multiple countries in Europe.
This trial is investigating JK06, an antibody-drug conjugate, for patients with advanced cancer that cannot be removed by surgery or has spread to other parts of the body. The study includes various cancer types, including gastric adenocarcinoma.
Inclusion criteria: Participants must be at least 18 years old and have advanced or metastatic cancer. They must have tried standard treatments or be unable to receive them. Women who can have children must have a negative pregnancy test and use effective birth control. Men with partners who can have children must use barrier contraception. Participants must be willing to attend clinic visits and follow study procedures. They must have a performance status of 0 or 1, meaning they are fully active or restricted in strenuous activity but able to carry out light work, and a life expectancy of at least 12 weeks.
Exclusion criteria: Patients who have had recent cancer treatment, have certain other health conditions, are pregnant or breastfeeding, have allergies to the study medication, are unable to follow study procedures, are participating in another clinical trial, have certain heart conditions, uncontrolled infections, or have had recent surgery cannot participate.
Focus: The trial has two phases. Phase 1 aims to find the right dose of JK06 by gradually increasing the amount given. Phase 2 will involve giving the selected dose to more patients to further evaluate its effects. Treatment is given every three weeks through intravenous infusion. Participants will be monitored closely for any side effects or changes in their condition.
Investigational drug: JK06 is an experimental antibody-drug conjugate that targets a protein called 5T4 on cancer cells. The drug combines an antibody with a chemotherapy agent to specifically target and attack cancer cells, potentially minimizing damage to normal cells.
This trial is comparing MK-2870 with physician's choice of treatment for patients with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma who have progressed after at least two previous treatments.
Inclusion criteria: Participants must have advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma confirmed by scans. They must have received and progressed after at least two previous treatments with chemotherapy or immunotherapy. If the cancer is HER2-positive, they must have previously received trastuzumab if appropriate. Participants must have adequate organ function, provide a tumor tissue sample to check for TROP2 protein, have measurable disease, and have an ECOG performance status of 0 or 1.
Exclusion criteria: Patients with other types of cancer, a different cancer in the past unless successfully treated, serious heart problems, uncontrolled high blood pressure, active infections requiring treatment, who are pregnant or breastfeeding, have known allergies to study medication, participated in another trial within 30 days, have a history of substance abuse, or have mental health conditions affecting participation cannot participate.
Focus: Participants will receive either MK-2870 or a physician-selected treatment including options like trifluridine-tipiracil, paclitaxel, docetaxel, or irinotecan. Medications are administered intravenously or orally depending on the specific drug. The study monitors disease progression, response rates, and adverse events.
Investigational drug: MK-2870 is an experimental medication being studied for its effectiveness and safety in treating advanced or metastatic gastroesophageal adenocarcinoma in patients who have tried at least two other therapies without success.
This trial studies whether adding zolbetuximab to pembrolizumab and chemotherapy works better than chemotherapy and pembrolizumab alone as a first treatment for HER2-negative gastric and gastroesophageal junction cancer that tests positive for CLDN18.2 and PD-L1 proteins.
Inclusion criteria: Participants must be at least 18 years old and have confirmed gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread to other parts of the body. The cancer must test positive for PD-L1 and CLDN18.2 proteins and be HER2-negative. They must be able to receive treatment with chemotherapy and pembrolizumab, have good physical function status (ECOG 0 or 1), and a life expectancy of at least 12 weeks.
Exclusion criteria: Patients with known allergies to study medications, previous chemotherapy for advanced cancer, active autoimmune disease requiring treatment, untreated or unstable brain metastases, other cancers within the last 5 years (except certain successfully treated cancers), significant heart conditions, active hepatitis or tuberculosis infections, who are pregnant or breastfeeding, unable to swallow oral medications, major surgery within 4 weeks, participation in another trial within 4 weeks, or conditions that would make participation unsafe cannot participate.
Focus: Participants receive either zolbetuximab or placebo along with pembrolizumab and chemotherapy (either CAPOX or mFOLFOX6). All medications are given through intravenous infusion, with some chemotherapy taken as tablets. The study tracks how long participants live, whether cancer grows or spreads, and monitors side effects.
Investigational drugs: Zolbetuximab targets Claudin 18.2 protein on cancer cell surfaces, helping the immune system recognize and attack cancer cells. Pembrolizumab blocks PD-L1 protein to help the immune system detect and fight cancer cells. CAPOX and mFOLFOX6 are chemotherapy combinations that work together to kill cancer cells or stop them from growing.
This trial tests whether a new imaging method using [18F]FAPI-74 PET/CT can detect oesophagogastric adenocarcinoma and pancreatic ductal adenocarcinoma better than current standard methods in newly diagnosed, treatment-naive patients.
Inclusion criteria: Participants must be 18 years or older and provide voluntary written informed consent. They must have a new diagnosis of oesophagogastric adenocarcinoma or pancreatic ductal adenocarcinoma confirmed by histology or cytology, with cancer classified as cT1-4N0-3M0 for OGA or cT1-4N0-2M0-1 for PDAC. They must have had or be scheduled for an [18F]FDG PET/CT scan within 4 weeks, or for PDAC patients, conventional CT or MRI of the upper abdomen within 4 weeks.
Exclusion criteria: Patients who have already received cancer treatment, have other serious health conditions, are pregnant or breastfeeding, are unable to give informed consent, have allergies to substances used in the study, or are participating in another clinical trial cannot participate.
Focus: Participants undergo PET/CT scanning using the [18F]AlF-FAPI-74 imaging agent, which is injected intravenously. The scan aims to detect cancer-associated fibroblasts and provide better information about cancer presence and extent compared to conventional imaging methods.
Investigational drug: [18F]AlF-FAPI-74 is a radiopharmaceutical imaging agent that targets fibroblast activation protein, which is often overexpressed in cancer-associated fibroblasts, allowing for enhanced imaging of tumors in PET/CT scans.
This trial explores a gut microbiome intervention (EXL01) combined with nivolumab immunotherapy and FOLFOX chemotherapy as first-line treatment for patients with metastatic gastric cancer showing high levels of PD-L1 protein.
Inclusion criteria: Participants must sign informed consent, provide tumor tissue samples, be registered in a national health care system, and be at least 18 years old. Women must not be pregnant or breastfeeding and agree to use birth control. Men who are fertile must agree to use birth control and not donate sperm. Participants must have advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 expression, have not received prior treatment for advanced disease (except certain therapies completed at least 6 months before), have measurable tumors, ECOG performance status 0 or 1, adequate blood and organ function, and appropriate QT interval measurements.
Exclusion criteria: Patients with other types of cancer in the past (unless not expected to return), serious heart problems, uncontrolled high blood pressure, active infections requiring antibiotics, known allergies to study drugs, who are pregnant or breastfeeding, have autoimmune disease, had major surgery within 4 weeks, are participating in another clinical trial, or have a history of substance abuse cannot participate.
Focus: Participants receive EXL01 orally in capsule form, nivolumab and FOLFOX components (oxaliplatin and fluorouracil) via intravenous infusion. Treatment is given in cycles with regular monitoring and assessments to evaluate cancer response. The primary goal is to determine the objective response rate at 4 months.
Investigational drugs: EXL01 is a microbiome therapeutic designed to interact with gut bacteria to support immune function and enhance cancer treatment response. Nivolumab is an immunotherapy that blocks the PD-1 protein on immune cells, enhancing the immune system's ability to fight cancer. FOLFOX is a chemotherapy combination that interferes with DNA replication and cell division to kill cancer cells.
This trial tests ifinatamab deruxtecan on various types of cancers that have either come back or spread, including gastric, esophageal, and other cancers. The study evaluates the medication's effectiveness and safety.
Inclusion criteria: Participants must be at least 18 years old, have recurrent or metastatic cancer with at least one measurable lesion on CT or MRI scans, have ECOG performance status of 0 or 1, adequate organ function, documented disease progression after previous treatments, and have received prior treatments specific to their cancer type. They must not have received certain types of chemotherapy before.
Exclusion criteria: Patients with recurrent or metastatic solid tumors including the specified cancer types, without target lesions as defined by RECIST v1.1, not within the specified age range, or who are part of a vulnerable population cannot participate.
Focus: Participants receive ifinatamab deruxtecan as a solution for intravenous infusion. The study monitors the body's response to treatment and tracks any side effects or changes in condition through regular visits and assessments.
Investigational drug: Ifinatamab deruxtecan is an antibody-drug conjugate that targets specific proteins on cancer cells, delivering a cytotoxic agent directly to tumors to help kill cancer cells or stop them from growing.
This trial investigates whether adding PIPAC to chemotherapy increases the number of patients who can undergo surgery aimed at completely removing gastric adenocarcinoma that has spread to the peritoneum.
Inclusion criteria: Participants must be between 18-75 years old, have a first diagnosis of primary gastric adenocarcinoma with positive peritoneal cytology and/or disease in the abdomen with PCI of 6 or less confirmed by tissue test, sign informed consent, have ECOG PS scale of 0-1, and if of childbearing potential, will be monitored with pregnancy tests and use appropriate contraceptives.
Exclusion criteria: Patients who do not have gastric adenocarcinoma with peritoneal metastases or are not within the specified age range cannot participate.
Focus: Participants receive either chemotherapy alone (Arm A) or chemotherapy combined with PIPAC (Arm B). Chemotherapy includes fluorouracil, docetaxel, nivolumab, oxaliplatin, and calcium levofolinate administered intravenously. PIPAC involves cisplatin and doxorubicin hydrochloride administered intraperitoneally. The study monitors treatment response, side effects, and evaluates whether surgery becomes possible.
Investigational drugs: PIPAC is a therapy that delivers chemotherapy directly into the abdominal cavity as a pressurized aerosol to target cancer cells more effectively. CRS and HIPEC are surgical procedures involving tumor removal and heated chemotherapy applied directly inside the abdomen after surgery to kill remaining cancer cells.
This trial explores new drug combinations including rilvegostomig with chemotherapy for patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Inclusion criteria: Participants must be 18 years or older, weigh more than 35 kg, have locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, not have received previous treatment for this cancer, have measurable disease according to RECIST 1.1, ECOG PS of 0 or 1, life expectancy of at least 12 weeks, and adequate organ and bone marrow function.
Exclusion criteria: Patients with other types of cancer, previous treatments that might interfere with study results, other serious health conditions, who are pregnant or breastfeeding, unable to follow study procedures, participated in another trial recently, have allergies to study medication, have a history of substance abuse, an active infection, or a mental health condition cannot participate.
Focus: Participants are randomly assigned to receive either FOLFOX or TFOX chemotherapy regimens. FOLFOX includes fluorouracil, calcium levofolinate, and oxaliplatin. TFOX adds anhydrous docetaxel to FOLFOX. All medications are administered intravenously in cycles. The study evaluates objective response rate and progression-free survival at 6 months.
Investigational drugs: The novel agent being tested in combination with chemotherapy aims to improve treatment outcomes by potentially shrinking tumors or stopping their growth. Chemotherapy uses drugs to kill cancer cells or stop them from growing.
This trial tests combinations of zongertinib with either trastuzumab deruxtecan or trastuzumab emtansine for patients with HER2-positive metastatic breast cancer and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
Inclusion criteria: Participants must be 18 years or older, have documented HER2-positive metastatic breast cancer or metastatic gastric, esophageal, or gastroesophageal junction adenocarcinoma, provide tumor tissue from areas not previously treated with radiation if possible, have documented disease progression, at least one measurable lesion according to RECIST 1.1, ECOG score of 0 or 1, and adequate organ function.
Exclusion criteria: Patients with other types of cancer, unable to follow treatment plan and schedule, have started other anti-cancer treatments before study treatment shows results, are part of a vulnerable population cannot participate.
Focus: Phase Ib involves gradually increasing the dose of zongertinib to determine the maximum tolerated dose when combined with either trastuzumab deruxtecan or trastuzumab emtansine. Phase II aims to find the most effective dose for further development. Participants receive zongertinib orally as a film-coated tablet and either trastuzumab deruxtecan or trastuzumab emtansine intravenously.
Investigational drugs: Zongertinib is an oral medication being tested to determine the best tolerable dose when combined with other treatments. Trastuzumab deruxtecan and trastuzumab emtansine are intravenous medications that target HER2-positive cancer cells by delivering chemotherapy directly to them.
This trial investigates the combination of durvalumab and tremelimumab immunotherapy medications for patients with resectable gastric or gastroesophageal junction cancer characterized by microsatellite instability and without Epstein-Barr virus infection.
Inclusion criteria: Participants must provide written informed consent, be at least 18 years old, have ECOG Performance Status of 0-1, weigh more than 30 kg, have resectable gastric or gastroesophageal junction cancer without distant metastases confirmed by imaging, life expectancy of at least 12 weeks, MSI-high status confirmed and EBV-negative, adequate bone marrow and organ function, and be able to access treatment and follow-up at the participating center.
Exclusion criteria: Patients with cancer that has spread to other organs, cancer that cannot be surgically removed, cancer that does not show microsatellite instability, or cancer with EBV infection cannot participate.
Focus: Participants receive durvalumab and tremelimumab through intravenous infusion before surgery or as definitive treatment. The study monitors cancer response to immunotherapy, tracking whether cancer disappears completely, how long participants live without cancer recurrence, and overall survival rates.
Investigational drugs: Tremelimumab blocks a protein that prevents the immune system from attacking cancer cells, allowing better targeting and destruction of cancer cells. Durvalumab blocks a different protein (PD-L1) on cancer cells, enhancing the body's natural defenses to fight cancer.
This trial evaluates the combination of bemarituzumab with FLOT chemotherapy (fluorouracil, levoleucovorin, oxaliplatin, and docetaxel) given before and after surgery for patients with gastric and gastroesophageal junction adenocarcinoma whose cancer cells show FGFR2b overexpression.
Inclusion criteria: Participants must sign informed consent, be willing to attend visits and follow treatment schedule, have confirmed gastric or gastroesophageal junction adenocarcinoma, provide tumor tissue for FGFR2b analysis showing positive overexpression status, have ECOG performance status 0 or 1, cancer classified as cT2-T4a or N+ without distant spread, adequate blood and organ function including specific levels of liver enzymes, albumin, bone marrow function, kidney function, and blood clotting function, be at least 18 years old, and agree to use contraception if of childbearing potential.
Exclusion criteria: Patients with other types of cancer, previous treatment with similar drugs, certain other health conditions, who are pregnant or breastfeeding, unable to follow study procedures, have allergies to study drugs, participated in another trial recently cannot participate.
Focus: Participants receive bemarituzumab combined with FLOT chemotherapy through intravenous infusion over six months. Treatment is given before surgery to shrink tumors and after surgery to eliminate remaining cancer cells. The study monitors treatment response, side effects, and overall patient health.
Investigational drug: Bemarituzumab is a monoclonal antibody that targets and blocks the FGFR2b protein on cancer cells, helping to slow down or stop cancer cell growth when combined with FLOT chemotherapy.
These 22 ongoing clinical trials represent a diverse range of treatment approaches for adenocarcinoma gastric across Europe. Several key observations emerge from this overview:
Geographic distribution: Trials are concentrated in Western and Southern Europe, with France, Italy, Spain, Germany, Belgium, and Poland hosting the most studies. This distribution reflects both the clinical research infrastructure in these countries and the disease burden.
Treatment approaches: The trials explore three main therapeutic strategies. Immunotherapy combinations, particularly involving pembrolizumab, appear in multiple trials, often combined with chemotherapy. Several studies focus on antibody-drug conjugates including trastuzumab deruxtecan, ifinatamab deruxtecan, and JK06. Targeted therapies like zolbetuximab targeting Claudin 18.2 protein feature prominently in several trials.
Patient populations: Most trials target advanced, metastatic, or unresectable disease, though some studies focus on resectable cancer with neoadjuvant or perioperative treatment approaches. Many trials specify biomarker requirements such as HER2 status, PD-L1 expression, Claudin 18.2 positivity, or microsatellite instability.
Treatment settings: The majority of trials investigate first-line treatment options, though several focus on patients who have progressed after previous therapies. Some studies explore novel combinations of existing treatments or compare experimental regimens to standard care.
The variety of approaches being tested reflects the complexity of gastric adenocarcinoma and the need for personalized treatment strategies based on tumor characteristics and patient factors. These trials collectively aim to improve outcomes for patients with this challenging disease.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
